News
New Scientific Research provides link between Globo-series glycosphingolipids (GSLs) antigens and tumor survival in Breast Cancer
Study supports the anti-Globo series Cancer pipeline under development by OBI Pharma Inc. TAIPEI, TAIWAN / — A team led by Dr. Chi-Huey Wong, Distinguished Research …
OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference
SAN FRANCISCO, CA. January 8, 2019 /PRNewswire/ — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Amy Huang, General Manager, will present a …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
First Orphan Drug Designation for OBI-888, a novel first-in-class Monoclonal Antibody targeting Globo H, a glycolipid antigen found on multiple tumor types. TAIPEI, Taiwan, November …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid and liquid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan. …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
First Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan, July 9, …